SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies Inc. (QCLS) is actively trending amid excitement over its strategic positioning in cutting-edge quantum-class computing and photonic technology, bolstered by the recent appointment of an OpenAI AI systems leader to its board. Community discussions highlight strong belief in the company's potential, with many anticipating significant upside due to its perceived undervaluation and growing calls for a short squeeze. Investors are closely monitoring price action, navigating persistent market manipulation concerns while noting the high short interest.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its earnings report, where a Q4 beat was overshadowed by soft Q1 guidance due to supply constraints, leading to a significant sell-off. The community is sharply divided, with many investors viewing it as an overreaction and a buying opportunity based on long-term foundry ambitions and government backing. Others, however, see it as a justified correction for an overvalued stock facing ongoing execution challenges, fueling intense debate about its immediate future.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is experiencing a surge in attention and trading volume, ignited by recent Breakthrough Therapy Designation for its Pemvidutide program targeting MASH. Community discussions are heavily centered on the drug's "best-in-class" potential for MASH and weight loss with lean mass preservation, leading to widespread speculation of a strategic partnership or acquisition, though some also voice concerns regarding historical trial data.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is experiencing a fierce rally, driven by increasing memory demand, reported industry shortages, and analyst upgrades, with recent news of major price hikes from industry players further fueling the sector's "supercycle." This has ignited a passionate debate, as bulls foresee continued parabolic growth into upcoming earnings, while bears caution of an unsustainable bubble and potential market manipulation, drawing comparisons to previous high-flying stocks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is currently trending with strong anticipation for significant news ahead of its upcoming earnings, as the community speculates about new, large-scale AI infrastructure deals that could solidify its pivot from Bitcoin mining. Traders are actively discussing the stock's remarkable resilience and 'unreal strength,' with many looking for breakout opportunities and short squeezes, believing that any dips represent a chance to load up before a potential major upward move.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after breaking ground on its substantial Delta Forge 1 AI factory campus, widely interpreted by the community as a strong signal of an imminent hyperscaler lease agreement. While many investors are bullish and anticipate a significant surge in valuation as the company expands its AI infrastructure, others point to perceived market manipulation by shorts aiming to acquire shares at lower prices.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending after the US updated deep-sea mining regulations, enabling the company to file a consolidated application that significantly expands its exploration territory. The community is highly bullish, anticipating rapid permit approval and future production as a critical move for national security and reducing reliance on foreign mineral supply chains. Many expect substantial upside and a potential short squeeze, driven by perceived government backing and the urgency to secure essential resources for industries like EVs.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano (MOVE) is trending as its merger partner, Corvex, secured a long-term NVIDIA H200 GPU deployment to scale AI infrastructure, igniting speculative interest. The community is heavily focused on MOVE's ultra-low float, anticipating a significant short squeeze, and actively debating its potential for further volatile price action amidst the AI narrative.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is generating significant conversation among investors, many of whom are keenly awaiting updates on new AI/HPC data center contracts amid perceived silence from management. While some express frustration over market manipulation and the stock's lagging performance compared to peers, others remain bullish, citing its strong position in the growing AI infrastructure sector and anticipating a potential short squeeze. The debate centers on whether the company can capitalize on its strategic alliances and overcome current market skepticism.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is actively trending due to its exceptionally dedicated and relentlessly building community, which consistently launches diverse real-world products and initiatives, establishing itself as a unique 'permissionless brand'. Enthusiastic holders are continually discussing its long-term vision and ongoing IRL developments across various blockchain ecosystems like ETH, SOL, and BASE.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bio-Path Holdings Inc.’s stock (BPTH) soared over 150% Thursday afternoon, hitting levels last seen in August, making it the second-biggest gainer across U.S. exchanges.&nbsp;The surge followed the company’s announcement of promising preclinical data for its drug candidate BP1001-A, targeting obesity and related metabolic disorders in Type 2 diabetes patients.The preclinical studies revealed that BP1001-A enhances insulin sensitivity by downregulating growth factor receptor-bound protein 2 (Grb2), which plays a crucial role in insulin signaling.&nbsp;By targeting Grb2, the treatment demonstrated potential in lowering blood glucose levels. This approach is seen as a promising alternative to current weight loss drugs that struggle to show efficacy in obese patients with Type 2 diabetes.Bio-Path CEO Peter Nielsen said, “The failure of leading weight loss medications to induce weight loss in obese patients who have Type 2 diabetes creates a compelling need for an alternative method of lowering blood glucose in obese patients who have Type 2 diabetes.”"We are excited by the rapid progress we have made advancing BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients based on previous BP1001-A preclinical studies as they support our continued and rapid development of this promising program,” he added.The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BPTH_sentiment_and_messahe_volume_Dec_20_4b61c6386d.png" alt="BPTH sentiment and messahe volume Dec 20.png" width="1318" height="324"><figcaption>BPTH sentiment and message volume Dec 20 as of 2:00 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, Bio-Path became a trending symbol, with sentiment turning ‘extremely bullish’ as message volume reached its highest point this year.&nbsp;Many retail investors expressed enthusiasm for accumulating the stock during after-hours trading to counter potential short-seller activity.<stembedurl>https://stocktwits.com/Henry666666/message/597231530</stembedurl><stembedurl>https://stocktwits.com/dpell17/message/597231919</stembedurl><stembedurl>https://stocktwits.com/Trader1141/message/597221863</stembedurl>In October, Bio-Path shares surged after the company announced its development program for BP1001-A. While the drug is being explored for obesity and metabolic diseases, it is also undergoing a Phase 1/1b trial for solid tumors.Despite the dramatic single-day rally, the stock remains down over 80% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market data with uptrend vector | Illustration Source: Getty Images

Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode

The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.

Equity

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Bio-Path Holdings Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

Current Price	$0.064
Prev Close	$0.067
Open	$0.067
Dividend Yield	0.00%
50-Day Moving Average	$0.0715
Beta	0.95
Avg. Volume	23,242.91
PE Ratio	-0.04

52-Week High	$0.2316
52-Week Low	$0.0501
Market Capitalization	$502,773.00
EPS (Annual)	-$4.12
Price to Book	-0.08
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BPTH
Bio-Path Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BPTH News

BPTHBio-Path Holdings Inc